\contentsline {chapter}{Glossary}{xii}{section*.4}
\contentsline {chapter}{Acronyms}{xiii}{section*.6}
\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}Genetics and Molecular Biology in Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{5}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{6}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{6}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{7}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{8}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{10}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Sequencing Technologies}{10}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{11}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{12}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{13}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{14}{subsubsection.1.1.5.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.1}Findings from Cancer Genomes}{14}{subsubsubsection.1.1.5.1.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.2}Genomic Comparisons Across Cancer Tissues}{16}{subsubsubsection.1.1.5.1.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.1.3}Cancer Genomic Data Resources}{17}{subsubsubsection.1.1.5.1.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{17}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{18}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{18}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{19}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{20}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{20}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{21}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{23}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{24}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{25}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{25}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{26}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{27}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{28}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{28}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{30}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{32}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{33}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{36}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{36}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{37}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{40}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{42}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{43}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{46}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{47}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{47}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{47}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{48}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{48}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{48}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{49}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{49}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{49}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{51}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{51}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occurring Mutations}{51}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{52}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{53}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{57}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{57}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{57}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{58}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{59}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{60}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{60}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{60}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{62}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{62}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{63}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{63}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{64}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{65}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{65}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{65}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{66}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{67}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{68}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{68}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{69}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{69}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{69}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{70}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{70}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{72}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{74}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{76}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{76}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{79}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{79}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{83}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{86}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{86}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{88}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{91}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{98}{subsubsection.3.3.2.2}
\contentsline {subsubsubsection}{\numberline {3.3.2.2.1}Importance of Directional Testing}{98}{subsubsubsection.3.3.2.2.1}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{100}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{100}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{101}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Hierarchy Based on Biological Context}{102}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{103}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{107}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{107}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{108}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{110}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{110}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{110}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{111}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{111}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{112}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{113}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{114}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{116}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{117}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{120}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{123}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with siRNA screen candidates}{123}{subsection.4.2.1}
\contentsline {subsubsection}{\numberline {4.2.1.1}Comparison with correlation}{124}{subsubsection.4.2.1.1}
\contentsline {subsubsection}{\numberline {4.2.1.2}Comparison with viability}{125}{subsubsection.4.2.1.2}
\contentsline {subsubsection}{\numberline {4.2.1.3}Comparison with secondary siRNA screen candidates}{129}{subsubsection.4.2.1.3}
\contentsline {subsubsection}{\numberline {4.2.1.4}Comparison of screen at pathway level}{129}{subsubsection.4.2.1.4}
\contentsline {subsubsubsection}{\numberline {4.2.1.4.1}Resampling of genes for pathway enrichment}{131}{subsubsubsection.4.2.1.4.1}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{137}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway expression}{137}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic mutation}{140}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Mutation locus}{141}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Synthetic lethal metagenes}{143}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}Replication in stomach cancer}{145}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Synthetic Lethal Genes and Pathways}{145}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Synthetic Lethal Expression Profiles}{147}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Comparison to Primary Screen}{149}{subsection.4.4.3}
\contentsline {subsubsection}{\numberline {4.4.3.1}Resampling Analysis}{150}{subsubsection.4.4.3.1}
\contentsline {subsection}{\numberline {4.4.4}Metagene Analysis}{150}{subsection.4.4.4}
\contentsline {section}{\numberline {4.5}Global Synthetic Lethality}{151}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Hub Genes}{152}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Hub Pathways}{154}{subsection.4.5.2}
\contentsline {section}{\numberline {4.6}Replication in cell line encyclopaedia}{155}{section.4.6}
\contentsline {section}{\numberline {4.7}Discussion}{157}{section.4.7}
\contentsline {subsection}{\numberline {4.7.1}Strengths of the SLIPT Methodology}{157}{subsection.4.7.1}
\contentsline {subsection}{\numberline {4.7.2}Syntheic Lethal Pathways for E-cadherin}{158}{subsection.4.7.2}
\contentsline {subsection}{\numberline {4.7.3}Replication and Validation}{160}{subsection.4.7.3}
\contentsline {subsubsection}{\numberline {4.7.3.1}Integration with siRNA Screening}{160}{subsubsection.4.7.3.1}
\contentsline {subsubsection}{\numberline {4.7.3.2}Replication across Tissues and Cell lines}{161}{subsubsection.4.7.3.2}
\contentsline {section}{\numberline {4.8}Summary}{162}{section.4.8}
\contentsline {paragraph}{Aims}{164}{section*.75}
\contentsline {paragraph}{Summary}{164}{section*.76}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{165}{chapter.5}
\contentsline {paragraph}{Aims}{165}{section*.8}
\contentsline {paragraph}{Summary}{165}{section*.9}
\contentsline {section}{\numberline {5.1}Synthetic Lethal Genes in Reactome Pathways}{167}{section.5.1}
\contentsline {subsection}{\numberline {5.1.1}The PI3K/AKT Pathway}{167}{subsection.5.1.1}
\contentsline {subsection}{\numberline {5.1.2}The Extracellular Matrix}{169}{subsection.5.1.2}
\contentsline {subsection}{\numberline {5.1.3}G Protein Coupled Receptors}{172}{subsection.5.1.3}
\contentsline {subsection}{\numberline {5.1.4}Gene Regulation and Translation}{172}{subsection.5.1.4}
\contentsline {section}{\numberline {5.2}Network Analysis of Synthetic Lethal Genes}{173}{section.5.2}
\contentsline {subsection}{\numberline {5.2.1}Gene Connectivity and Vertex Degree}{173}{subsection.5.2.1}
\contentsline {subsection}{\numberline {5.2.2}Gene Importance and Centrality}{175}{subsection.5.2.2}
\contentsline {subsubsection}{\numberline {5.2.2.1}Information Centrality}{175}{subsubsection.5.2.2.1}
\contentsline {subsubsection}{\numberline {5.2.2.2}PageRank Centrality}{178}{subsubsection.5.2.2.2}
\contentsline {section}{\numberline {5.3}Testing Pathway Structure of Synthetic Lethal Genes}{179}{section.5.3}
\contentsline {subsection}{\numberline {5.3.1}Hierarchical Pathway Structure}{179}{subsection.5.3.1}
\contentsline {subsubsection}{\numberline {5.3.1.1}Contextual Hierarchy of PI3K}{179}{subsubsection.5.3.1.1}
\contentsline {subsubsection}{\numberline {5.3.1.2}Testing Contextual Hierarchy of Synthetic Lethal Genes}{179}{subsubsection.5.3.1.2}
\contentsline {subsection}{\numberline {5.3.2}Upstream or Downstream Synthetic Lethality}{183}{subsection.5.3.2}
\contentsline {subsubsection}{\numberline {5.3.2.1}Measuring Structure of Candidates within PI3K}{183}{subsubsection.5.3.2.1}
\contentsline {subsubsection}{\numberline {5.3.2.2}Testing Synthetic Lethal Pathway Structure by Resampling}{185}{subsubsection.5.3.2.2}
\contentsline {section}{\numberline {5.4}Discussion}{186}{section.5.4}
\contentsline {section}{\numberline {5.5}Conclusion}{186}{section.5.5}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{186}{chapter.6}
\contentsline {paragraph}{Aims}{186}{section*.100}
\contentsline {paragraph}{Summary}{186}{section*.101}
\contentsline {section}{\numberline {6.1}Simulations and Modelling Synthetic Lethality in Expression Data}{189}{section.6.1}
\contentsline {section}{\numberline {6.2}Simulations over simple graph structures}{190}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance}{190}{subsection.6.2.1}
\contentsline {subsection}{\numberline {6.2.2}Synthetic lethality across graph stuctures}{190}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Performance with inhibition links}{190}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance with 20,000 genes}{190}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations over pathway-based graphs}{190}{section.6.3}
\contentsline {section}{\numberline {6.4}Comparing methods}{190}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}SLIPT and Chi-Squared}{190}{subsection.6.4.1}
\contentsline {subsubsection}{\numberline {6.4.1.1}Correlated query genes}{190}{subsubsection.6.4.1.1}
\contentsline {subsection}{\numberline {6.4.2}Correlation}{190}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Bimodality with BiSEp}{190}{subsection.6.4.3}
\contentsline {chapter}{\numberline {7}Discussion}{191}{chapter.7}
\contentsline {paragraph}{Aims}{191}{section*.8}
\contentsline {paragraph}{Summary}{191}{section*.9}
\contentsline {section}{\numberline {7.1}Significance}{193}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{194}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{195}{section.7.3}
\contentsline {chapter}{\numberline {8}Conclusion}{197}{chapter.8}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{198}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {A}Sample Quality}{223}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{223}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{226}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{230}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{239}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{241}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{241}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Expression Profiles}{244}{section.D.2}
\contentsline {section}{\numberline {D.3}Comparison to Primary Screen}{247}{section.D.3}
\contentsline {subsection}{\numberline {D.3.1}Resampling Analysis}{249}{subsection.D.3.1}
\contentsline {section}{\numberline {D.4}Compare SLIPT genes}{251}{section.D.4}
\contentsline {section}{\numberline {D.5}Metagene Analysis}{253}{section.D.5}
\contentsline {section}{\numberline {D.6}Mutation Variation}{254}{section.D.6}
\contentsline {subsection}{\numberline {D.6.1}Mutation Frequency}{254}{subsection.D.6.1}
\contentsline {subsection}{\numberline {D.6.2}PI3K Mutation Expression}{255}{subsection.D.6.2}
\contentsline {chapter}{\numberline {E}Metagene Expression Profiles}{258}{appendix.E}
\contentsline {chapter}{\numberline {F}Stomach Expression Analysis}{264}{appendix.F}
\contentsline {section}{\numberline {F.1}Synthetic Lethal Genes and Pathways}{264}{section.F.1}
\contentsline {section}{\numberline {F.2}Comparison to Primary Screen}{267}{section.F.2}
\contentsline {subsection}{\numberline {F.2.1}Resampling Analysis}{269}{subsection.F.2.1}
\contentsline {section}{\numberline {F.3}Metagene Analysis}{271}{section.F.3}
\contentsline {chapter}{\numberline {G}Stomach Mutation Analysis}{272}{appendix.G}
\contentsline {section}{\numberline {G.1}Synthetic Lethal Genes and Pathways}{272}{section.G.1}
\contentsline {section}{\numberline {G.2}Synthetic Lethal Expression Profiles}{275}{section.G.2}
\contentsline {section}{\numberline {G.3}Comparison to Primary Screen}{278}{section.G.3}
\contentsline {subsection}{\numberline {G.3.1}Resampling Analysis}{280}{subsection.G.3.1}
\contentsline {section}{\numberline {G.4}Metagene Analysis}{282}{section.G.4}
\contentsline {chapter}{\numberline {H}Global Synthetic Lethality in Stomach Cancer}{283}{appendix.H}
\contentsline {section}{\numberline {H.1}Hub Genes}{285}{section.H.1}
\contentsline {section}{\numberline {H.2}Hub Pathways}{286}{section.H.2}
\contentsline {chapter}{\numberline {I}Replication in cell line encyclopaedia}{287}{appendix.I}
